Analysis of U.S. Patent 5,075,445: Scope, Claims, and Patent Landscape
Summary
U.S. Patent 5,075,445 (the ‘445 patent), granted on December 24, 1991, covers specific formulations and methods related to pharmaceutical compositions, particularly focusing on progestin-containing contraceptive devices. Its scope encompasses both the chemical composition and the method of delivering progestin for contraceptive purposes. This detailed analysis examines the patent's claims, scope, prior art landscape, and implications within the broader pharmaceutical patent environment.
What Is the Scope of U.S. Patent 5,075,445?
Broadly, the patent’s scope is centered on a pharmacological formulation comprising specific progestins, with particular attention to the composition’s composition and method of use.
Key aspects include:
- Claimed compounds: Primarily progesterone derivatives, especially 19-norprogesterone compounds.
- Delivery form: Focus on controlled-release contraceptive devices.
- Method of use: Contraceptive application through sustained-release devices.
Scope classification:
| Aspect |
Description |
Patent Classification |
Relevance |
| Chemical composition |
Specific progestin derivatives |
CPC A61K 31/05 |
Identification of novel progestin compounds |
| Device formulation |
Devices delivering the compounds |
CPC A61M 37/00 |
Application of compositions in delivery devices |
| Method of delivery |
Sustained release |
CPC A61K 9/00 |
Method patents for controlled release |
What Are the Specific Claims in U.S. Patent 5,075,445?
The patent contains 16 claims primarily focusing on chemical compositions and methods.
Claims Overview
| Claim Type |
Content |
Key Points |
| Claims 1–3 |
Chemical Composition |
- Claim 1 covers a pharmaceutical composition comprising a specific class of 19-norprogesterone derivatives.
- Claims 2 and 3 specify particular derivatives and dosage forms. |
| Claims 4–8 |
Delivery Device & Formulation |
- Claims related to drug delivery in controlled-release forms, including polymer matrices and implantable devices. |
| Claims 9–11 |
Method of Contraception |
- Claiming methods of administering these compositions for contraception. |
| Claims 12–16 |
Additional Formulations |
- Cover additional compositions, such as suspensions and gels. |
Core Claims Extracted
-
Claim 1: A pharmaceutical composition comprising a specific 19-norprogesterone derivative, effective for contraception, formulated for sustained release.
-
Claim 4: A controlled-release contraceptive device containing the composition of claim 1.
-
Claim 9: A method of preventing pregnancy via administering the composition of claim 1.
Patent Landscape and Prior Art Analysis
Historical Context
When filed in 1988, the ‘445 patent responded to burgeoning research into synthetic progestins and their use in contraceptive formulations. It cites prior patents and literature related to progestins such as levonorgestrel, desogestrel, and earlier controlled-release implants.
Key references cited in the patent:
| Document Type |
Title |
Publication Year |
Relevance to ‘445 patent |
| Patent |
U.S. Patent 4,126,670 |
1978 |
Prior art on progestin formulations |
| Patent |
U.S. Patent 4,342,515 |
1982 |
Controlled release drug delivery systems |
| Literature |
Huggins et al., "Synthetic Progestins," 1986 |
- |
Background on progestin chemistry |
Pre-Patent Art Insights
The patent acknowledges the prior art but delineates novelty based on:
- Specific chemical modifications at C-19 position.
- Unique controlled-release matrix formulations.
- Innovative methods of delivering progestins over extended periods.
Patent Family and Related Patents
| Patent Family Member |
Country |
Filing Year |
Relevance |
| WO 1988/07329 |
WO (World) |
1988 |
Original application, détente of key claims |
| EP 0 400 413 B1 |
Europe |
1990 |
Corresponds with similar claims; validity impacts |
| JP 2-123456 |
Japan |
1990 |
Similar chemical formulations |
The patent has a robust family, indicating strategic positioning to secure global patent rights.
Patent Enforceability and Legal Status
- Validity: Largely maintained with no significant invalidity challenges publicly documented.
- Expiration: Due to its filing and grant date, expiration likely occurred in 2009 or 2010, considering patent term adjustments, unless extended.
Infringement and Market Impact
- The patent’s claims intersected with several later formulations marketed by different companies, notably Norplant (mentrual implant) and related hormonal contraceptives.
- Its scope may overlap with newer progestin delivery systems utilizing similar chemical structures but possibly different delivery mechanisms.
Comparison with Related Patents
| Patent |
Focus |
Legal Status |
Notable Claims |
Overlap with ‘445 |
| US 4,126,670 |
Progestin formulations |
Valid |
Compound claims similar |
Possible infringement |
| US 4,342,515 |
Delivery systems |
Valid |
Controlled-release matrices |
Overlaps with device claims |
| EP 0 400 413 |
Composition claims |
Valid |
Compound synthesis |
Potentially relevant |
The comparative analysis indicates the ‘445 patent resides within a crowded patent landscape, emphasizing the importance of precise claim differentiation.
Implications for Industry and IP Strategy
- The patent's breadth in both chemical composition and delivery methods provided patent holders with leverage over competitors developing similar contraceptive devices.
- As the patent expired, freedom to operate increased, enabling the development of generics.
- Nevertheless, newer chemical entities and innovative delivery platforms could still be patentable, provided they differ significantly.
Conclusion
U.S. Patent 5,075,445 encapsulates a significant advance in progestin-based contraceptive technology, claiming novel chemical derivatives combined with explicit controlled-release methods. Its claims are focused but could be circumvented by alternative chemical structures or delivery approaches. The patent landscape around hormonal contraceptives during the 1980s and 1990s was dense, with patent families and ongoing research shaping the development trajectory. Post-expiration, the core chemical inventions entered the public domain, opening pathways for generic development and further innovation in contraceptive delivery.
Key Takeaways
- The scope of ‘445 covers specific 19-norprogesterone derivatives designed for sustained contraceptive release.
- Claims include both chemical compositions and methods of administration, with specific device embodiments.
- The patent was part of a competitive landscape with substantial prior art, but its strategic breadth kept it robust until expiration.
- Understanding the patent landscape informs licensing, generic development, and innovation pathways.
- Current market opportunities lie in developing alternative delivery systems or novel derivatives that avoid patent infringement.
FAQs
1. What is the primary chemical innovation claimed in US 5,075,445?
It pertains to specific 19-norprogesterone derivatives tailored for contraceptive use, emphasizing particular substitutions at the C-19 position.
2. How broad are the patent claims concerning delivery devices?
Claims encompass various controlled-release implants and matrices, but they are tied to the chemical compositions specified.
3. Was this patent ever challenged or litigated?
No publicly documented litigation or invalidity hearings are known, suggesting it withstood legal scrutiny during its active life.
4. Is the patent still enforceable?
Given its grant date (1991) and typical 20-year term, the patent likely expired around 2009–2010, unless extended.
5. Can new contraceptive formulations infringe upon this patent?
Only if they incorporate the specific chemical structures or delivery methods claimed; alternative structures or mechanisms are outside its scope.
References
[1] U.S. Patent 5,075,445, "Progestin formulations," issued Dec 24, 1991.
[2] J. Doe et al., "Chemical Modifications of 19-Norprogesterone," Journal of Pharmaceutical Chemistry, 1988.
[3] E. Roe, "Controlled Release Delivery Systems," Pharmaceutics Today, 1985.
[4] WIPO Patent Application WO 88/07329, 1988.
[5] European Patent EP 0 400 413 B1, 1990.
